Functional Improvement Seen With Govorestat in SORD Deficien

The phase 3 double-blind, placebo-controlled INSPIRE trial included 56 patients aged 16 to 55 years with genetically-confirmed SORD deficiency

Related Keywords

Riccardo Perfetti , Health Index , Chief Medical Officer ,